TELUS Health Annual Conference 2023

With the increasing cost of specialty drugs and drugs for rare diseases, real-world evidence (RWE) is being leveraged by researchers, payors and clinicians around the world to assess disease burden across populations, perform risk adjustment, improve clinical trial datasets, and more. Where does Canada stand in the generation of RWE for assessing new and existing drugs? How can RWE bring value to drug assessment for private benefits plans? How are carriers addressing the need for better evidence? Can RWE be used to support outcomes-based agreements? Led by industry experts, this panel discussion sheds light on current challenges, risks and opportunities.